SixPeaks Bio (acquired by AstraZeneca)

1. Executive Summary (Confidence: High)

SixPeaks Bio represents a significant strategic acquisition in the global obesity market, which is projected to reach US$100 to 150 billion by the mid-2030s. Founded in 2022 as part of Versant Ventures’ Ridgeline Discovery Engine in Basel, the company emerged from stealth in 2024 and was acquired by AstraZeneca in late October 2024 for up to $300 million. The acquisition hands AstraZeneca control of a preclinical pipeline centered on activin type II receptor (ActRIIA/IIB) blockade, a mechanism designed to counteract the muscle loss (sarcopenia) that often accompanies GLP-1 therapy. This deal utilizes a "build-to-buy" model, highlighting the industry's shift toward functional weight management solutions that prioritize "healthy" weight loss over simple calorie reduction.